UroGen Pharma (URGN) Q3 2025: Zesturi Prescriber Base Hits 54 as J-Code Bottleneck Delays Full Uptake
Zesturi, UroGen’s new bladder cancer therapy, is experiencing strong physician interest but is materially constrained by reimbursement logistics, with a permanent J-code set to unlock broader adoption in 2026. Gelmito, the established franchise, continued steady expansion, offsetting heavy launch investment. Management’s tone signals high conviction in the long-term market opportunity, but the near-term revenue ramp depends on resolving operational bottlenecks and accelerating patient conversions.
Summary
- Physician Demand Deferred: Prescriber interest in Zesturi is robust, but administrative hurdles and lack of a permanent J-code are delaying widespread adoption.
- Gelmito Remains Anchor: Core Gelmito franchise continues to deliver consistent growth and provides a cash-flow foundation for pipeline investment.
- 2026 Inflection Point: Permanent J-code expected to materially accelerate Zesturi uptake, especially in community practices, reshaping revenue trajectory.
Performance Analysis
UroGen’s Q3 2025 results demonstrate a business navigating the complexities of a major new product launch against a backdrop of stable legacy growth. Total revenues reached $27.5 million, with Gelmito, the mitomycin gel for upper tract urothelial cancer, contributing $25.7 million, up 13% year-over-year on an underlying basis. Zesturi, the recently launched first-in-class treatment for low-grade intermediate-risk non-muscle-invasive bladder cancer, delivered $1.8 million in its initial full quarter, with October preliminary demand revenue of $4.5 million signaling sequential momentum.
Commercial investment weighed on the bottom line, as selling, general, and administrative expenses rose sharply to $37.6 million (from $28.9 million), reflecting the onboarding of 30 new sales reps and broader field infrastructure. R&D spend increased to $14 million, driven by the UGN-103 Phase III trial. Net loss widened to $33.3 million, with cash reserves at $127.4 million providing a runway through the launch phase. Management reaffirmed full-year Gelmito revenue guidance of $94 to $98 million and unchanged operating expense targets.
- Launch Drag: Zesturi’s early sales remain limited by a 45–60 day lag from patient enrollment to dosing, tied to reimbursement and operational complexity.
- Field Force Expansion: Sales and support teams now total 130, reflecting a deliberate investment to drive both new and legacy product growth.
- Underlying Demand Signals: Patient enrollment forms and site activations are tracking ahead of legacy launches, indicating pent-up demand once bottlenecks clear.
The quarter underscores UroGen’s dual-track execution: legacy product stability, offsetting launch drag, and a pipeline that could drive a step-change in growth once operational barriers are removed.
Executive Commentary
"While we had expected a faster uptake, there are many factors that support our belief that the near and long-term opportunity for Zesturi is on track. The preliminary demand revenue for October is more than double the previous three months, demonstrating increased usage and adoption... We expect to see an acceleration in adoption once the permanent product-specific J-code goes into effect on January 1, 2026."
Liz Barrett, President and Chief Executive Officer
"We continue to expect 2025 Gelmito net product revenues to be in the range of $94 to $98 million... We continue to believe that we do have cash to profitability, but, you know, we will continue and remain disciplined in terms of how we think about and be opportunistic, you know, future capital needs."
Chris Degnan, Chief Financial Officer
Strategic Positioning
1. Zesturi Launch: Structural Barriers and Latent Demand
Zesturi, the only FDA-approved therapy for low-grade intermediate-risk non-muscle-invasive bladder cancer, addresses a $5 billion annual market. While prescriber enthusiasm and patient enrollment forms (“PEFs”) are strong, conversion from PEF to treatment is delayed by reimbursement hurdles, notably the use of a temporary miscellaneous J-code. This bottleneck is most acute in community practices, which represent the largest untapped segment—the majority of physicians are waiting for the permanent J-code before prescribing, with full adoption expected to accelerate in 2026.
2. Gelmito: Foundation for Growth and Cash Flow
Gelmito’s established position as standard of care in upper tract urothelial cancer provides a stable revenue and cash flow base. Prescriber confidence remains high, and the expanded field team is driving incremental growth. Gross-to-net adjustments have normalized, offering clearer visibility into underlying demand. The “reverse halo” effect—where Zesturi discussions are generating new Gelmito users—demonstrates synergistic portfolio leverage.
3. Pipeline Focus and Portfolio Rationalization
UroGen is concentrating resources on next-generation mitomycin programs (UGN-103, UGN-104) and the oncolytic virus asset UGN-501, after discontinuing UGN-301 due to lack of compelling efficacy. UGN-103’s Phase III data is consistent with prior trials, and a new drug application is planned for 2026. UGN-501, positioned for high-grade disease and potentially beyond urology, is entering IND-enabling studies with a first-in-human trial expected in 2026.
Key Considerations
Q3 2025 marks a transition period for UroGen, with the Zesturi launch facing friction but underpinned by strong latent demand and operational groundwork. The company’s dual focus on commercial execution and pipeline advancement shapes the investment debate for 2026 and beyond.
Key Considerations:
- J-Code as Adoption Catalyst: Most community urologists are waiting for the permanent J-code, which will streamline reimbursement and accelerate uptake.
- Conversion Lag: The current 45–60 day lag from PEF to dosing is expected to fall below 30 days over the course of 2026, improving revenue recognition cadence.
- Site Activation vs. Utilization: Nearly 600 sites are activated for Zesturi, but site readiness does not yet translate to high utilization until reimbursement is simplified.
- Operating Expense Leverage: Heavy SG&A investment is front-loaded; future revenue growth is needed to absorb fixed costs and move toward profitability.
Risks
Key risks center on execution and timing: a slower-than-expected reduction in conversion lag, persistent reimbursement friction, or delays in J-code-driven adoption could prolong unprofitable operations. There is also pipeline development risk, particularly as UroGen pivots resources to next-generation assets. Competitive entrants in bladder cancer and evolving payer dynamics are additional variables to monitor.
Forward Outlook
For Q4 2025, UroGen guided to:
- Continued sequential growth in Zesturi demand revenue, with full acceleration expected post-J-code in 2026
- Gelmito net product revenues for 2025 in the $94 to $98 million range
For full-year 2025, management maintained guidance:
- Operating expenses of $215 to $225 million, including $11 to $14 million in non-cash share-based compensation
Management highlighted:
- Gradual improvement in conversion lag as operational experience builds and reimbursement workflows are streamlined
- Broader Zesturi adoption in community practices once the permanent J-code becomes effective in January 2026
Takeaways
UroGen’s investment case hinges on Zesturi’s ability to transition from operationally constrained launch to broad market adoption in 2026, leveraging an established field force and a robust pipeline. Gelmito provides ballast, but future upside is tied to execution on the Zesturi ramp and next-generation product approvals.
- Launch Bottleneck: Zesturi’s near-term revenue is artificially capped by reimbursement friction, but underlying demand signals are strong and building.
- Portfolio Synergy: The expanded field force and cross-promotion are driving incremental Gelmito growth and seeding future pipeline launches.
- 2026 as Pivotal Year: Investors should watch for inflection in Zesturi adoption rates and conversion efficiency as the J-code goes live and operational hurdles are cleared.
Conclusion
UroGen is at the cusp of a major commercial inflection, with Zesturi poised for rapid expansion once reimbursement barriers fall. Execution on conversion efficiency and continued pipeline progress will determine whether the company can translate clinical advances into durable shareholder value.
Industry Read-Through
UroGen’s experience highlights the critical role of reimbursement infrastructure in specialty pharma launches, especially for buy-and-bill therapies in oncology. The lag between clinical enthusiasm and commercial realization underscores the importance of operational readiness and payer alignment. Other companies introducing first-in-class therapies should anticipate similar friction, particularly when introducing new treatment paradigms into community practice. The dynamic between hospital and community uptake, and the need for robust field support, are instructive for peers navigating complex launches in urology and adjacent specialties.